Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade

Jul 24 2012

• By Peter Chang

Related Content

Biosimilars Development Should Target “Residual Uncertainty,” FDA Says

Jul 23 2012

Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma

Oct 10 2011

Korea's Celltrion In Deal With U.S.-based Hospira For Biogeneric Sales; M&A Hinted At

Oct 12 2009

Korea FDA Unveils Initial Biosimilar Guidance; Final Guidelines To Be Released In July

Jun 29 2009

Related Companies

Celltrion, Inc.

Johnson & Johnson

Hospira, Inc.

Nippon Kayaku Co., Ltd.

Egis Pharmaceuticals PLC

Abbott

Amgen, Inc.

UCB S.A.

Additional Topics

South Korea Asia Pacific Business Strategies Regulation BioPharmaceutical

More from South Korea

More from Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window